Literature DB >> 27350618

Hepatitis C virus infection stimulates transforming growth factor-β1 expression through up-regulating miR-192.

Ji Hyun Kim1, Chang Ho Lee1, Seong-Wook Lee2.   

Abstract

The objective of this study was to determine the molecular mechanisms underlying chronic liver injury and fibrosis caused by hepatitis C virus (HCV). This study revealed that miR-192 expreßsion was induced by HCV infection without affecting viral replication. However, viral-induced miR-192 up-regulated transforming growth factor-ß1 (TGF-ß1) expreßsion in liver cells at transcriptional level. TGF-ß1 stimulation by HCV-induced miR-192 was caused through ZEB1 down-regulation and TGF-ß1 increased miR-192 level via positive feedback pathway. Increase in miR-192 expreßsion by HCV infection was due to HCV core protein released and/or expressed by viral infection. TGF-ß1 promoter activity was also increased by HCV core protein in liver cells. Taken together, HCV infection resulted in increased TGF-ß1 transcription in hepatocytes through ZEB1 down-regulation by HCV core-mediated miR-192 stimulation. Importantly, miR-192 inhibition with anti-miR-192 rescued ZEB1 expression down-regulated by HCV infection, thus reducing the level of TGF-ß1 expression increased by HCV infection in hepatocytes. These results suggest a novel mechanism of HCV-mediated liver fibrogenesis with miR-192 being a potential molecular target to ameliorate viral pathogenesis.

Entities:  

Keywords:  TGF-β1; ZEB1; hepatitis C Virus; liver fibrosis; miR-192

Mesh:

Substances:

Year:  2016        PMID: 27350618     DOI: 10.1007/s12275-016-6240-3

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  43 in total

1.  Characterization of the promoter region of the human transforming growth factor-beta 1 gene.

Authors:  S J Kim; A Glick; M B Sporn; A B Roberts
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

Review 2.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

3.  Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.

Authors:  Hisashi Ishida; Tomohide Tatsumi; Atsushi Hosui; Takatoshi Nawa; Takahiro Kodama; Satoshi Shimizu; Hayato Hikita; Naoki Hiramatsu; Tatsuya Kanto; Norio Hayashi; Tetsuo Takehara
Journal:  Biochem Biophys Res Commun       Date:  2011-07-23       Impact factor: 3.575

4.  Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122.

Authors:  A J van der Meer; W R R Farid; M J Sonneveld; P E de Ruiter; A Boonstra; A J van Vuuren; J Verheij; B E Hansen; R J de Knegt; L J W van der Laan; H L A Janssen
Journal:  J Viral Hepat       Date:  2012-08-27       Impact factor: 3.728

5.  Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway.

Authors:  Antonio A Postigo
Journal:  EMBO J       Date:  2003-05-15       Impact factor: 11.598

6.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

7.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

8.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

Review 9.  Translational biomarkers of acetaminophen-induced acute liver injury.

Authors:  Richard D Beger; Sudeepa Bhattacharyya; Xi Yang; Pritmohinder S Gill; Laura K Schnackenberg; Jinchun Sun; Laura P James
Journal:  Arch Toxicol       Date:  2015-05-17       Impact factor: 5.153

10.  Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase.

Authors:  Chang Ho Lee; Young Ju Lee; Ji Hyun Kim; Jong Hoon Lim; Jung-Hye Kim; Wonkyo Han; Soo-Han Lee; Gyu-Jeong Noh; Seong-Wook Lee
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

View more
  11 in total

1.  Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model.

Authors:  Reina Sasaki; Pradip Devhare; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

2.  According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.

Authors:  Elia Moreno-Cubero; Dolores Subirá; Eduardo Sanz-de-Villalobos; Trinidad Parra-Cid; Antonio Madejón; Joaquín Miquel; Antonio Olveira; Alejandro González-Praetorius; Javier García-Samaniego; Juan-Ramón Larrubia
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 3.  Exosomal miRNAs: novel players in viral infection.

Authors:  Javid Sadri Nahand; Maryam Mahjoubin-Tehran; Mohsen Moghoofei; Mohammad Hossein Pourhanifeh; Hamid Reza Mirzaei; Zatollah Asemi; Alireza Khatami; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Epigenomics       Date:  2020-02-25       Impact factor: 4.778

4.  ZEB1 serves an oncogenic role in the tumourigenesis of HCC by promoting cell proliferation, migration, and inhibiting apoptosis via Wnt/β-catenin signaling pathway.

Authors:  Liang-Yun Li; Jun-Fa Yang; Fan Rong; Zhi-Pan Luo; Shuang Hu; Hui Fang; Ying Wu; Rui Yao; Wei-Hao Kong; Xiao-Wen Feng; Bang-Jie Chen; Jun Li; Tao Xu
Journal:  Acta Pharmacol Sin       Date:  2021-01-29       Impact factor: 7.169

Review 5.  miRNAs regulate immune response and signaling during hepatitis C virus infection.

Authors:  Huange Zhu; Yan Geng; Qian He; Miaoxian Li
Journal:  Eur J Med Res       Date:  2018-04-18       Impact factor: 2.175

Review 6.  Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis.

Authors:  Mousumi Khatun; Ratna B Ray
Journal:  Cells       Date:  2019-10-14       Impact factor: 6.600

7.  Complexation with Random Methyl-β-Cyclodextrin and (2-Hidroxypropyl)-β-Cyclodextrin Enhances In Vivo Anti-Fibrotic and Anti-Inflammatory Effects of Chrysin via the Inhibition of NF-κB and TGF-β1/Smad Signaling Pathways and Modulation of Hepatic Pro/Anti-Fibrotic miRNA.

Authors:  Alina Ciceu; Cornel Balta; Hidegard Herman; Sami Gharbia; Simona-Rebeca Ignat; Sorina Dinescu; Judit Váradi; Ferenc Fenyvesi; Szilvia Gyöngyösi; Anca Hermenean; Marieta Costache
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

Review 8.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

Review 9.  Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history.

Authors:  Julia Peña-Asensio; Eduardo Sanz-de-Villalobos; Joaquín Miquel; Juan Ramón Larrubia
Journal:  World J Hepatol       Date:  2020-10-27

10.  Rotavirus-Mediated Suppression of miRNA-192 Family and miRNA-181a Activates Wnt/β-Catenin Signaling Pathway: An In Vitro Study.

Authors:  Anwesha Banerjee; Mamta Chawla-Sarkar; Anupam Mukherjee
Journal:  Viruses       Date:  2022-03-09       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.